Lamivudine And Zidovudine Tablet, Film Coated
Product Images NDC 72865-144

8 FDA label images from Xlcare Pharmaceuticals, Inc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Lamivudine And Zidovudine (NDC 72865-144). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xlcare Pharmaceuticals, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

15 mg/300 mg-60 Ct (Lamivudine And Zidovudine Cl 60 Ct)

15 mg/300 mg-60 Ct (Lamivudine And Zidovudine Cl 60 Ct)
Label for Lamivudine and Zidovudine Tablets, USP 150 mg/300 mg film-coated tablets by XLcare Pharmaceuticals, Inc. The label shows the NDC 72865-144, contains 60 tablets, and indicates prescription use only. Includes storage instructions, dosage reference, and manufacturing details for XLcare Pharmaceuticals and Ascent Pharmaceuticals.*
FDA Label Image

Structure-lamivudine (Struct Lamivudine)

Structure-lamivudine (Struct Lamivudine)
Chemical structure of lamivudine, showing its molecular arrangement with atoms and bonds depicted in a 2D diagram.*
FDA Label Image

Structure-zidovudine (Struct Zidovudine)

Structure-zidovudine (Struct Zidovudine)
Chemical structure of lamivudine, one of the active ingredients in the lamivudine and zidovudine oral tablet combination product by XLCare Pharmaceuticals, Inc.*
FDA Label Image

Table 1 (Table 1)

Table 1 (Table 1)
A data table titled 'Selected Clinical Adverse Reactions (Greater than or Equal to 5% Frequency)' from 4 controlled clinical trials with EPIIVIR 300 mg per day and RETROVIR 600 mg per day. It lists various adverse reactions by body system and their frequency percentages among 251 patients, including headache (35%), nausea (33%), nasal symptoms (20%), and musculoskeletal pain (12%).*
FDA Label Image

Table 2 (Table 2)

Table 2 (Table 2)
A data table showing frequencies of selected laboratory abnormalities among adults in four controlled clinical trials of EPIVIR 300 mg/day plus RETROVIR 600 mg/day. The table lists abnormal test levels for neutropenia, anemia, thrombocytopenia, ALT, AST, bilirubin, and amylase, along with corresponding percentages and number of subjects assessed. Footnotes clarify abbreviations and note the higher frequency of abnormalities in subjects with mild baseline laboratory abnormalities.*
FDA Label Image

Table 3 (Table 3)

Table 3 (Table 3)
A pharmacokinetic parameters table comparing lamivudine and zidovudine in adults. It presents data on oral bioavailability, apparent volume of distribution, plasma protein binding, CSF-to-plasma ratio, systemic clearance, renal clearance, and elimination half-life with corresponding sample sizes and variability measures.*
FDA Label Image

Table 4 (Table 4)

Table 4 (Table 4)
A table titled 'Effect of Coadministered Drugs on Lamivudine and Zidovudine AUC' showing various coadministered drugs with their doses, numbers of subjects (n), changes in lamivudine or zidovudine concentrations (AUC) including percentage increase or decrease with confidence intervals or ranges, and notes on the concentration changes of the coadministered drugs. The table lists multiple drugs such as Nelfinavir, Trimethoprim/Sulfamethoxazole, Atovaquone, Clarithromycin, among others, with corresponding statistical data.*
FDA Label Image

Table 5 (Table 5)

Table 5 (Table 5)
A data table titled 'Number of Subjects (%) with at Least 1 HIV-1 Disease-Progression Event or Death' summarizing patient outcomes across three therapy groups: Current Therapy, EPIVIR plus Current Therapy, and EPIVIR plus a NNRTI plus Current Therapy. The table lists endpoints of HIV-1 progression or death and death, with corresponding numbers and percentages of subjects for each group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.